Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL CECILE RENARD PHARMACIEN : revenue, balance sheet and financial ratios

SPFPL CECILE RENARD PHARMACIEN is a French company founded 3 years ago, specialized in the sector Gestion de fonds. Based in BELLEVILLE-EN-BEAUJOLAIS (69220), this company of category PME shows in 2025 a net income positive of 31 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPL CECILE RENARD PHARMACIEN (SIREN 913961074)
Indicator 2025 2024 2023
Revenue N/C N/C N/C
Net income 30 701 € 29 480 € -17 793 €
EBITDA -1 965 € -2 048 € -17 278 €
Net margin N/C N/C N/C

Revenue and income statement

In 2025, SPFPL CECILE RENARD PHARMACIEN generates positive net income of 31 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-1 965 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-1 965 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

30 701 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 1891%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 5%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 26.7 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

1891.214%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

5.022%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

26.728

Solvency indicators evolution
SPFPL CECILE RENARD PHARMACIEN

Sector positioning

Debt ratio
1891.21 2025
2023
2024
2025
Q1: 0.0
Med: 11.05
Q3: 95.16
Watch +50 pts over 3 years

In 2025, the debt ratio of SPFPL CECILE RENARD PHARM... (1891.21) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
5.02% 2025
2023
2024
2025
Q1: 9.51%
Med: 52.2%
Q3: 89.36%
Average

In 2025, the financial autonomy of SPFPL CECILE RENARD PHARM... (5.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
26.73 years 2025
2023
2024
2025
Q1: 0.0 years
Med: 0.12 years
Q3: 3.48 years
Average +50 pts over 3 years

In 2025, the repayment capacity of SPFPL CECILE RENARD PHARM... (26.73) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-78.117

Liquidity indicators evolution
SPFPL CECILE RENARD PHARMACIEN

Sector positioning

Interest coverage
-78.12x 2025
2023
2024
2025
Q1: -76.3x
Med: 0.0x
Q3: 0.0x
Average -24 pts over 3 years

In 2025, the interest coverage of SPFPL CECILE RENARD PHARM... (-78.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Positioning of SPFPL CECILE RENARD PHARMACIEN in its sector

Comparison with sector Gestion de fonds

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (40 transactions). This range of 39 860€ to 229 717€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2025
Indicative
39k€ 78k€ 229k€
78 624 € Range: 39 860€ - 229 717€
NAF 5 année 2025

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 40 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Gestion de fonds)

Compare SPFPL CECILE RENARD PHARMACIEN with other companies in the same sector:

Voir toutes les statistiques du secteur Gestion de fonds

Frequently asked questions about SPFPL CECILE RENARD PHARMACIEN

What is the revenue of SPFPL CECILE RENARD PHARMACIEN ?

The revenue of SPFPL CECILE RENARD PHARMACIEN is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPL CECILE RENARD PHARMACIEN profitable?

Yes, SPFPL CECILE RENARD PHARMACIEN generated a net profit of 31 k€ in 2025.

Where is the headquarters of SPFPL CECILE RENARD PHARMACIEN ?

The headquarters of SPFPL CECILE RENARD PHARMACIEN is located in BELLEVILLE-EN-BEAUJOLAIS (69220), in the department Rhone.

Where to find the tax return of SPFPL CECILE RENARD PHARMACIEN ?

The tax return of SPFPL CECILE RENARD PHARMACIEN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL CECILE RENARD PHARMACIEN operate?

SPFPL CECILE RENARD PHARMACIEN operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.